CoChat

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Open access
Qin, Shukui, Chan, Stephen L, Gu, Shanzhi, Bai, Yuxian, Ren, Zhenggang, Lin, Xiaoyan, Chen, Zhendong, Jia, Weidong, Jin, Yongdong, Guo, Yabing, Hu, Xiaohua, Meng, Zhiqiang, Liang, Jun, Cheng, Ying, Xiong, Jianping, Ren, Hong, Yang, Fang, Li, Wei, Chen, Yajin, Zeng, Yong, Sultanbaev, Alexander, Pazgan-Simon, Monika, Pisetska, Margaryta, Melisi, Davide, Ponomarenko, Dmitriy, Osypchuk, Yurii, Sinielnikov, Ivan, Yang, Tsai-Sheng, Liang, Xiao, Chen, Chunxia, Wang, Linna, Cheng, Ann-Lii, Kaseb, Ahmed, Vogel, Arndt, Qin, Shukui, Chan, Stephen L, Cheng, Ann-Lii, Kaseb, Ahmed, Vogel, Arndt, Gu, Shanzhi, Bai, Yuxian, Ren, Zhenggang, Lin, Xiaoyan, Chen, Zhendong, Jia, Weidong, Jin, Yongdong, Guo, Yabing, Hu, Xiaohua, Meng, Zhiqiang, Liang, Jun, Cheng, Ying, Xiong, Jianping, Ren, Hong, Yang, Fang, Li, Wei, Chen, Yajin, Zeng, Yong, Sultanbaev, Alexander, Pazgan-Simon, Monika, Pisetska, Margaryta, Melisi, Davide, Ponomarenko, Dmitriy, Osypchuk, Yurii, Sinielnikov, Ivan, Yang, Tsai-Sheng, Liang, Xiao, Chen, Chunxia, Wang, Linna, Zhang, Mingxiang, Xu, Li, Yuan, Xianglin, Li, Da, Ying, Jierer, Zhang, Jingdong, Zhang, Tao, Gu, Kangsheng, He, Yifu, Hao, Ping, Jiang, Da, Zhang, Shu, Xing, Baocai, Zhang, Baihong, Wang, Dong, Zhai, Xiaofeng, Liang, Houjie, Cybulska-Stopa, Bozena, Dvorkin, Mikhail, Stroyakovskiy, Daniil, Nechaeva, Marina, Yen, Chia-Jui, Su, Wei-Wen, Chen, Yen-Hao, Bondarenko, Igor, Yang, Lin, Fang, Weijia, Gomez-Martin, Carlos, Ryu, Min-Hee, Kim, Han-Sang, Kim, Jee-Hyun, Zarubenkov, Oleg, Orlova, Rashida, Poddubskaya, Elena, Fadeeva, Natalia, Makarova, Yulia, Chao, Yee, Hung, Chao-Hung, Neffa, Maryna, Vynnychenko, Oleksandr, Burgoyne, Adam, Hao, Chunyi, Mohr, Raphael U, Diaz-Beveridge, Roberto, Feliu-Batlle, Jaime, Cubillo-Gracian, Antonio, Lee, Ann-Shing, Daniele, Bruno, Antonuzzo, Lorenzo, Sangiovanni, Angelo, Gasbarrini, Antonio, Scartozzi, Mario, Ahn, Mi Sun, Oh, Sung-Yong, Orlov, Sergey, Harputluoglu, Hakan, Oksuzoglu, Berna, Hsu, Chiun, Rau, Kun-Ming, Krechkovskyi, Oleksandr, Yareshko, Vladimir, Xiong, Henry, Lee, Fa-Chyi, Jiang, Yixing, Gabayan, Afshin, Crow, Mary, Van Steenkiste, Christophe, Verset, Gontran · 2023 · The Lancet

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.Methods This randomised, open-label, international phase 3 trial (CARES-310) was done at 95 study sites across 13 countries and regions worldwide. Patients with unresectable or metastatic hepatocellular carcinoma who had not previously received any systemic treatment were randomly assigned (1:1) to receive either camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily or sorafenib 400 mg orally twice daily. Randomisation was done via a centralised interactive response system. The primary endpoints were progression-free survival, as assessed by the blinded independent review committee per Response Evaluation Criteria in Solid Tumours version 1.1, and overall survival in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of the study drugs. We report the findings from the prespecified primary analysis for progression-free survival and interim analysis for overall survival. This study is registered with ClinicalTrials.gov (NCT03764293).Findings Between June 28, 2019, and March 24, 2021, 543 patients were randomly assigned to the camrelizumab-rivoceranib (n=272) or sorafenib (n=271) group. At the primary analysis for progression-free survival (May 10, 2021), median follow-up was 7·8 months (IQR 4·1-10·6). Median progression-free survival was significantly improved with camrelizumab-rivoceranib versus sorafenib (5·6 months [95% CI 5·5-6·3] vs 3·7 months [2·8-3·7]; hazard ratio [HR] 0·52 [95% CI 0·41-0·65]; one-sided p<0·0001). At the interim analysis for overall survival (Feb 8, 2022), median follow-up was 14·5 months (IQR 9·1-18·7). Median overall survival was significantly extended with camrelizumab-rivoceranib versus sorafenib (22·1 months [95% CI 19·1-27·2] vs 15·2 months [13·0-18·5]; HR 0·62 [95% CI 0·49-0·80]; one-sided p<0·0001). The most common grade 3 or 4 treatment-related adverse events were hypertension (102 [38%] of 272 patients in the camrelizumab-rivoceranib group vs 40 [15%] of 269 patients in the sorafenib group), palmar-plantar erythrodysaesthesia syndrome (33 [12%] vs 41 [15%]), increased aspartate aminotransferase (45 [17%] vs 14 [5%]), and increased alanine aminotransferase (35 [13%] vs eight [3%]). Treatment-related serious adverse events were reported in 66 (24%) patients in the camrelizumab-rivoceranib group and 16 (6%) in the sorafenib group. Treatment-related death occurred in two patients: one patient in the camrelizumab-rivoceranib group (ie, multiple organ dysfunction syndrome) and one patient in the sorafenib group (ie, respiratory failure and circulatory collapse).Interpretation Camrelizumab plus rivoceranib showed a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma, presenting as a new and effective first-line treatment option for this population.Funding Jiangsu Hengrui Pharmaceuticals and Elevar Therapeutics.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)00961-3

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 47 references

Cited by

See all 775

Metadata

Authors
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., Zeng, Y., Sultanbaev, A., Pazgan-Simon, M., Pisetska, M., Melisi, D., Ponomarenko, D., Osypchuk, Y., Sinielnikov, I., Yang, T.-S., Liang, X., Chen, C., Wang, L., Cheng, A.-L., Kaseb, A., Vogel, A., Qin, S., Chan, S. L., Cheng, A.-L., Kaseb, A., Vogel, A., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., Zeng, Y., Sultanbaev, A., Pazgan-Simon, M., Pisetska, M., Melisi, D., Ponomarenko, D., Osypchuk, Y., Sinielnikov, I., Yang, T.-S., Liang, X., Chen, C., Wang, L., Zhang, M., Xu, L., Yuan, X., Li, D., Ying, J., Zhang, J., Zhang, T., Gu, K., He, Y., Hao, P., Jiang, D., Zhang, S., Xing, B., Zhang, B., Wang, D., Zhai, X., Liang, H., Cybulska-Stopa, B., Dvorkin, M., Stroyakovskiy, D., Nechaeva, M., Yen, C.-J., Su, W.-W., Chen, Y.-H., Bondarenko, I., Yang, L., Fang, W., Gomez-Martin, C., Ryu, M.-H., Kim, H.-S., Kim, J.-H., Zarubenkov, O., Orlova, R., Poddubskaya, E., Fadeeva, N., Makarova, Y., Chao, Y., Hung, C.-H., Neffa, M., Vynnychenko, O., Burgoyne, A., Hao, C., Mohr, R. U., Diaz-Beveridge, R., Feliu-Batlle, J., Cubillo-Gracian, A., Lee, A.-S., Daniele, B., Antonuzzo, L., Sangiovanni, A., Gasbarrini, A., Scartozzi, M., Ahn, M. S., Oh, S.-Y., Orlov, S., Harputluoglu, H., Oksuzoglu, B., Hsu, C., Rau, K.-M., Krechkovskyi, O., Yareshko, V., Xiong, H., Lee, F.-C., Jiang, Y., Gabayan, A., Crow, M., Van Steenkiste, C., & Verset, G.
Affiliations
  • National Taiwan University Hospital (TW)
  • University of Verona (IT)
  • Jilin Province Tumor Hospital (CN)
  • Nanfang Hospital (CN)
  • First Affiliated Hospital of Nanchang University (CN)
  • Nanjing University of Chinese Medicine (CN)
  • Jiangsu Hengrui Medicine (China) (CN)
  • Sun Yat-sen University (CN)
  • Chang Gung Memorial Hospital (TW)
  • The Sixth People's Hospital of Shenyang (CN)
  • First Affiliated Hospital of GuangXi Medical University (CN)
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-09
Volume
402
Issue
10408
Pages
1133-1146
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4385211938
Cited by
746
References
46
Citations by year
2026: 198 · 2025: 273 · 2024: 242 · 2023: 32
FWCI
125.96
Type
journal article
Language
en
Open access
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion, cc-by-nc-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
camrelizumab, apatinib, sorafenib, hepatocellular carcinoma, unresectable liver cancer, first-line therapy, immune checkpoint inhibitors, anti-PD-1 therapy, VEGFR-2 inhibitors, progression-free survival, overall survival, treatment safety
MeSH terms
Sorafenib, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Pyridines, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00961-3
The paper
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., Hu, X., Meng, Z., Liang, J., Cheng, Y., Xiong, J., Ren, H., Yang, F., Li, W., Chen, Y., . . . Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(23)00961-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.